It has been demonstrated in a model of breast cancer that FAM83A acts downstream of the EGFR signaling and exerts oncogenic properties by promoting tumor growth, and conferring resistance to EGFR-tyrosine kinase inhibitors [58]. This evidence concerns the gene SACK1A and breast cancer.